Client Situation
- US listed oncology biotech
- Platform technology with programs from late clinical to preclinical
- Market cap from $1bn to $100m to $10m
- Three CEOs in four years
Treehill Mission
Findings
- Phase III program non-viable; largest value in early-stage programs
- Silos of scientific and business teams not integrated into cohesive strategic effort
- Capital markets communication not in sync with pipeline prospects
Recommendations & Implementation
- Abandon late-stage program; freeing up resources for follow-ons
- Focused partnering campaign for mid-stage program; re-setting perception and yielding a significant partnership commitment
- Value creation trajectory plan for early-stage pipeline, fuelling equity story